Loading clinical trials...
Loading clinical trials...
Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma
Conditions
Interventions
Temsirolimus
Locations
18
Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Universität Erlangen-Nürnberg
Erlangen, Bavaria, Germany
Klinikum rechts der Isar der Technischen Universität
München, Bavaria, Germany
GYNAEKOLOGICUM Bremen
Bremen, City state Bremen, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Hamburg, Germany
Klinikum der J. W. Goethe-Universität
Frankfurt am Main, Hesse, Germany
Start Date
October 1, 2011
Primary Completion Date
June 1, 2015
Completion Date
November 1, 2015
Last Updated
February 29, 2016
NCT07213804
NCT06051695
NCT06885697
NCT07035587
NCT01789229
NCT02869568
Lead Sponsor
AGO Study Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions